Lifespan extension therapy:Tesaglitazar (AZ242), an insulin sensitizer,  may increase life span via up-regulation of its target gene BubR1, 19/October/2017, 11.14 pm

Natural product-derived therapy for attenuating associated with Myocardial infarction: Formononetin, found  in Trifolium pratense and Maackia amurensis, decreases GM-CSF (Granulocyte-macrophage colony-stimulating factor) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits left ventricular rupture, and promotes heart healing via up regulation of its target gene, 18/November/2017, 8.19 am
November 18, 2017
 Molecular therapy for Glaucoma:  Rosiglitaone, an  insulin sensitizer, increases Nmnat1 expression, increases NAD+ levels, improves neuroanl dysfunction, and protects against glaucoma via down regulation of its target gene, 18/October/2017, 11.25 pm
November 18, 2017
Show all

 What they say: Introduction: 

A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July  2014 issue of the journal  “EMBO”, by Prof Sinclair, North BJ, and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Lifespan extension therapy:T esaglitazar (AZ242), an insulin sensitizer,  may increase life span via up-regulation of its target gene BubR1


What is known? 

Netoglitazone has been shown to possess anti-hyperglycemic property. However, the exact mechanism of action is far from clear.


From Research Findings to Therapeutic Opportunity: 

This study suggests, for the first time, that Tesaglitazarby increasing the expression of its target gene, it may: (a) increase the expression of BuBR1; (b) decrease the expression of p70 S6 Kinase; and (c) regulate the expression of a number of longevity-promoting molecules (Fig. 1).

[easy_payment currency=”USD”]

Figure 1. A therapeutic mix encompassing Tesaglitazar may extend  mammalian life span via up regulation of BuBR1 and down regulation of p70 S6 Kinase

 

Thereby, it may: (1) increase insulin sensitivity; (2) increase thermogenesis, lipolysis and oxidative metabolism; (3) inhibit obesity; (4) attenuate cognitive impairment; (5) delay diseases of aging; (6) slow down cardiac aging; (7) promote resistance to bone, immune and motor dysfunction; (8) promote tissue rejuvenation; and (9) prolong median life span. Thus, pharmacological formulations encompassing “Tesaglitazar or its analogues, either alone or in combination with other drugs” may be used to extend the lifespan of an individual (fig. 1).


Details on the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $500#

Undisclosed mechanistic information: How a pharmaceutical mix encompassing Tesaglitazar increases the expression of BubR1 and extends mammalian life-span

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

# Research cooperation


References

Web: http://genomediscovery.org or http://newbioideas.com

CitationBoominathan, L., Lifespan extension therapy:T esaglitazar (AZ242), an insulin sensitizer,  may increase life span via up-regulation of its target gene BubR1, 19/October/2017, 11.14 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.